Associate Director, Marketing Thought Leader Liaison, East

United States

Apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

A Bachelor's degree and a minimum of 10 years of pharmaceutical or related industry experience are required. Prior experience working with Hepatology/Gastroenterology KOLs is preferred. Strong strategic thinking, analytical skills, project management experience, and proficiency in MS Office are essential. Approximately 65% domestic travel is expected.

Responsibilities

Develop and execute strategic plans for engaging Key Opinion Leaders (KOLs) and thought leaders in Hepatology and Gastroenterology. Build and maintain compliant relationships with healthcare professionals and internal teams. Collect and synthesize KOL insights to inform brand strategy and tactics. Contribute to marketing strategies for conferences and manage KOL-related initiatives. Analyze market data, ensure ethical program delivery, and serve as the primary point of contact for field teams regarding KOL engagement.

Skills

KOL engagement

Thought Leader Liaison

KOL mapping

Cross-functional collaboration

Marketing strategy

Medical Affairs collaboration

Congress planning

Field sales collaboration

Insights synthesis

Compliance in external engagement

Hepatology

Gastroenterology

IBAT inhibitor portfolio

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free